Bioblast Pharma reports first quarter 2016 financial results
Bioblast Pharma reported the net loss for the 2016 first quarter was $4.6 million, or $0.32 per share, compared with a net loss of $3.3 million, or $0.23 per share, in the prior year period. Cash and cash equivalents (including short-term bank deposits) totaled $21.6 million at March 31, 2016. May 25, 2016